Tecvayli — Percent Change (as a percent)

Products & Services · Percent Change (as a percent)

Johnson & Johnson Tecvayli — Percent Change (as a percent) decreased by 61.7% to 40.6% in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 54.0%, from 88.3% to 40.6%. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityVolatile
First reportedQ2 2024
Last reportedQ3 2025

How to read this metric

A positive percentage indicates accelerating sales momentum and market penetration, whereas a negative percentage suggests a deceleration in growth or potential market saturation.

Detailed definition

This metric measures the period-over-period percentage growth or decline in net sales for the Tecvayli product line. It...

Peer comparison

Comparable to year-over-year or quarter-over-quarter revenue growth rates for specific high-growth pharmaceutical products across the industry.

Metric ID: jnj_segment_tecvayli_percent_change_as_a_percent

Historical Data

5 periods
 Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25
Value70.4%88.3%57%106.1%40.6%
QoQ Change+25.4%-35.4%+86.1%-61.7%
YoY Change+50.7%-54.0%
Range40.6%106.1%
CAGR-42.3%
Avg YoY Growth-1.7%
Median YoY Growth-1.7%

Frequently Asked Questions

What is Johnson & Johnson's tecvayli — percent change (as a percent)?
Johnson & Johnson (JNJ) reported tecvayli — percent change (as a percent) of 40.6% in Q3 2025.
How has Johnson & Johnson's tecvayli — percent change (as a percent) changed year-over-year?
Johnson & Johnson's tecvayli — percent change (as a percent) decreased by 54.0% year-over-year, from 88.3% to 40.6%.
What does tecvayli — percent change (as a percent) mean?
The percentage growth or decline in sales for the Tecvayli product compared to a previous period.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.